Shots:
- Dimerix has granted Everest exclusive rights to commercialize DMX-200 for all indications incl. FSGS, in Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam & Philippines; Dimerix will retain rights outside the licensed regions
- Dimerix will continue funding & conducting the P-III (ACTION3) study, while Everest will manage regulatory filings, maintenance of the regulatory dossier & commercialization costs in the licensed territories. The companies will establish a Joint Steering Committee to advance DMX-200 in FSGS in the licensed territories
- As per the deal, Dimerix will receive $10M upfront, ~$30M in development & regulatory milestones, & ~$300M in commercial milestones, along with tiered royalties on net sales between 10-15% in Greater China, South Korea, & certain SE Asian countries
Ref: PRnewswire | Image: Dimerix & Everest | Press Release
Related News: Everest Medicine Licenses Civorebrutinib to Travere Therapeutics in a ~$1.14B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
